Skip to Content

Brentuximab Disease Interactions

There are 8 disease interactions with brentuximab:

Major

Brentuximab Vedotin (Includes Brentuximab) ↔ Hepatotoxicity

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

The use of brentuximab vedotin should be avoided in patients with moderate or severe hepatic impairment. Serious cases of hepatotoxicities have occurred in patients receiving this agent. Patients with preexisting liver disease, and those with elevated baseline liver enzymes may be at an increased risk. Monitor liver enzymes and bilirubin. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dose, or discontinuation of therapy.

Major

Brentuximab Vedotin (Includes Brentuximab) ↔ Infections

Severe Potential Hazard, Moderate plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Serious infections, including opportunistic infections have been reported with the use of brentuximab vedotin. Monitor patients closely for the development of any infection during treatment with this agent. JC virus infection resulting in progressive multifocal leukoencephalopathy (PML) has been reported in patients treated with this agent. A diagnosis of PML should be considered in any patient presenting with new-onset of neurological manifestations and a consultation with a neurologist is recommended. Hold therapy for any suspected case of PML and discontinue if a diagnosis of PML is confirmed.

Major

Monoclonal Antibodies (Includes Brentuximab) ↔ Tumor Lysis Syndrome

Severe Potential Hazard, Moderate plausibility

Applies to: Tumor Lysis Syndrome

Tumor lysis syndrome (TLS) has occurred in patients receiving certain monoclonal antibodies. Patients with high tumor burden and those with high circulating lymphocyte counts of greater than 25 X 10^9/L have a higher risk of developing TLS. Consider tumor lysis prophylaxis prior to the infusion with anti-hyperuricemics and hydration beginning 12 to 24 hours prior to infusion. It is recommended to correct electrolytes abnormalities, and monitor renal function in patients who develop TLS.

Moderate

Brentuximab Vedotin (Includes Brentuximab) ↔ Hematologic Toxicities

Moderate Potential Hazard, Moderate plausibility

Applies to: Neutropenia, Thrombocytopenia, Anemia

Hematological toxicities, including prolonged severe neutropenia, thrombocytopenia or anemia can occur with the use of brentuximab vedotin. It is recommended to monitor patients for fever and if appropriate, dose delays, reduction, or discontinuation of treatment should be considered.

Moderate

Brentuximab Vedotin (Includes Brentuximab) ↔ Peripheral Neuropathy

Moderate Potential Hazard, Moderate plausibility

Applies to: Peripheral Neuropathy

Peripheral neuropathy, predominantly sensory neuropathy has occurred in patients treated with brentuximab vedotin. It is recommended to monitor patients for symptoms of neuropathy and in those experiencing new or worsening peripheral neuropathy. It is recommended to delay, or change dosage, or discontinue treatment as appropriate.

Moderate

Brentuximab Vedotin (Includes Brentuximab) ↔ Pulmonary Toxicity

Moderate Potential Hazard, Moderate plausibility

Applies to: Pulmonary Impairment

Cases of noninfectious pulmonary toxicity including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome (ARDS), some with fatal outcomes, have been reported with the use of brentuximab vedotin. Care should be taken when using this agent in patients at risk of pulmonary events. Hold dose in the event of new or worsening of pulmonary complications until symptoms improve.

Moderate

Brentuximab Vedotin (Includes Brentuximab) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

The frequency of adverse reactions, including fatalities are increased in patients with severe renal impairment. It is recommended to avoid the use of this agent in patients with severe renal impairment.

Moderate

Brentuximab Vedotin -Gi Events

Moderate Potential Hazard, Moderate plausibility

Applies to: Gastrointestinal Obstruction

Cases of fatal and serious gastrointestinal complication have been reported with the use of brentuximab vedotin. Care should be taken when using this agent in patients with a history of gastrointestinal complications, as its use can increase the risk of perforation. Closely monitor for new or worsening of GI symptoms and treat according to clinical practices.

brentuximab drug Interactions

There are 606 drug interactions with brentuximab

brentuximab alcohol/food Interactions

There is 1 alcohol/food interaction with brentuximab

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide